FDA
-
-
-
-
-
-
-
NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal
-
-
-
-
-
-
-
NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer
-
-
-
-
-
-
322,134 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

